154 related articles for article (PubMed ID: 11004816)
1. [Maintenance therapy of mild form of GERD by H2 receptor antagonists].
Kurosawa S
Nihon Rinsho; 2000 Sep; 58(9):1859-64. PubMed ID: 11004816
[TBL] [Abstract][Full Text] [Related]
2. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
3. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.
Mainie I; Tutuian R; Castell DO
J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394
[TBL] [Abstract][Full Text] [Related]
4. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy.
Rackoff A; Agrawal A; Hila A; Mainie I; Tutuian R; Castell DO
Dis Esophagus; 2005; 18(6):370-3. PubMed ID: 16336606
[TBL] [Abstract][Full Text] [Related]
5. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.
Miyamoto M; Haruma K; Kuwabara M; Nagano M; Okamoto T; Tanaka M
J Gastroenterol Hepatol; 2007 May; 22(5):639-44. PubMed ID: 17444849
[TBL] [Abstract][Full Text] [Related]
6. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
Bardhan KD
Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.
Fackler WK; Ours TM; Vaezi MF; Richter JE
Gastroenterology; 2002 Mar; 122(3):625-32. PubMed ID: 11874994
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic approaches to reflux disease, focusing on acid secretion.
Kinoshita Y; Adachi K; Fujishiro H
J Gastroenterol; 2003 Mar; 38 Suppl 15():13-9. PubMed ID: 12698865
[TBL] [Abstract][Full Text] [Related]
9. The Effect of H
Shim YK; Kim N
Korean J Gastroenterol; 2017 Jul; 70(1):4-12. PubMed ID: 28728310
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis.
Hamamoto N; Hashimoto T; Adachi K; Hirakawa K; Ishihara S; Inoue H; Taniura H; Niigaki M; Sato S; Kushiyama Y; Suetsugu H; Miyake T; Kinoshita Y
J Gastroenterol Hepatol; 2005 Feb; 20(2):281-6. PubMed ID: 15683433
[TBL] [Abstract][Full Text] [Related]
11. Medical therapy of gastroesophageal reflux disease in secondary and tertiary care settings.
Tytgat GN
Yale J Biol Med; 1999; 72(2-3):219-26. PubMed ID: 10780584
[TBL] [Abstract][Full Text] [Related]
12. "Refractory GERD": acid, nonacid, or not GERD?
Vaezi MF
Am J Gastroenterol; 2004 Jun; 99(6):989-90. PubMed ID: 15180714
[TBL] [Abstract][Full Text] [Related]
13. The pharmacological management of gastroesophageal reflux disease.
Lowe RC; Wolfe MM
Minerva Gastroenterol Dietol; 2004 Sep; 50(3):227-37. PubMed ID: 15729198
[TBL] [Abstract][Full Text] [Related]
14. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
Xue S; Katz PO; Banerjee P; Tutuian R; Castell DO
Aliment Pharmacol Ther; 2001 Sep; 15(9):1351-6. PubMed ID: 11552905
[TBL] [Abstract][Full Text] [Related]
15. [PPI: new strategies for GERD].
Hoshino E; Ishiyama A; Tsuchida T
Nihon Rinsho; 2004 Aug; 62(8):1570-6. PubMed ID: 15344553
[TBL] [Abstract][Full Text] [Related]
16. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.
Orenstein SR; Gremse DA; Pantaleon CD; Kling DF; Rotenberg KS
Clin Ther; 2005 Apr; 27(4):472-83. PubMed ID: 15922820
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
18. Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.
Furuta K; Adachi K; Komazawa Y; Mihara T; Miki M; Azumi T; Fujisawa T; Katsube T; Kinoshita Y
J Gastroenterol Hepatol; 2006 Oct; 21(10):1581-5. PubMed ID: 16928220
[TBL] [Abstract][Full Text] [Related]
19. Management strategies for gastroesophageal reflux disease.
Bak YT
J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S49-53. PubMed ID: 15324382
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of H2 receptor antagonists in the treatment of gastroesophageal reflux disease and its symptoms.
Tougas G; Armstrong D
Can J Gastroenterol; 1997 Sep; 11 Suppl B():51B-54B. PubMed ID: 9347179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
